{
    "2018-07-31": [
        [
            {
                "time": "",
                "original_text": "华兰生物：具备年产3000万人份四价流感疫苗生产能力",
                "features": {
                    "keywords": [
                        "华兰生物",
                        "四价流感疫苗",
                        "生产能力"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "生物"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "医疗保健：从人用转向兽用 荐5股",
                "features": {
                    "keywords": [
                        "医疗保健",
                        "人用",
                        "兽用",
                        "荐股"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医疗",
                        "保健"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "医药生物行业周报：重点推荐低估值高成长龙头仁和药业",
                "features": {
                    "keywords": [
                        "医药生物",
                        "周报",
                        "低估值",
                        "高成长",
                        "仁和药业"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "生物"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "[优于大市评级]医药与健康护理行业信息点评：羟乙基淀粉适应症监管更加严格 有望利好白蛋白",
                "features": {
                    "keywords": [
                        "医药",
                        "健康护理",
                        "羟乙基淀粉",
                        "监管",
                        "白蛋白"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药",
                        "健康护理"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}